ARTICLE | Company News
Sprint Bioscience deal
July 25, 2016 7:00 AM UTC
Sprint granted an undisclosed U.S. company worldwide rights to develop and commercialize Sprint’s phosphatidylinositol-5-phosphate 4-kinase type II alpha (PIP4K2A) inhibitor program targeting tumor m...